Harvest Technologies Corp. (www.harvesttech.com) announced today it has signed an exclusive distribution agreement related to its BMAC(TM) System in the US for the orthopedic bone regeneration market with Eatontown, N.J.-based Osteotech Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine. Harvest's BMAC (Bone Marrow Aspirate Concentrate) System is a point-of-care device for concentrating a patient's own (autologous) bone marrow stem cells. The BMAC(TM) System derives bone marrow aspirate concentrate, which is a rich source of autologous adult stem cells, in just 15 minutes.
PLYMOUTH, Mass. (Business Wire EON) March 13, 2008 --
Harvest Technologies Corp. (www.harvesttech.com)
announced today it has signed an exclusive distribution agreement
related to its BMAC™
System in the US for the orthopedic bone regeneration
market with Eatontown, N.J.-based Osteotech Inc. (Nasdaq: OSTE),
a leader in the emerging field of biologic solutions for regenerative
medicine. Harvest’s BMAC (Bone Marrow
Aspirate Concentrate) System is a point-of-care device for concentrating
a patient’s own (autologous) bone marrow stem
cells. The BMAC™ System derives bone marrow
aspirate concentrate, which is a rich source of autologous adult stem
cells, in just 15 minutes.
The scientific literature establishes that successful bone regeneration
is a combination of cells, signal proteins and a quality scaffold. The
combination of Osteotech’s biologic bone
regeneration products with Harvest’s BMAC
will provide orthopedic surgeons a new powerful tool.
“We are very excited to be partnering with
Osteotech. As a leader in the osteobiologic market, Osteotech is the
perfect partner for our BMAC product. Our two technologies have the
potential to set a new standard for bone regeneration,”
said Gary
Tureski, President of Harvest Technologies.
Harvest
Technologies has a rich tradition of innovative technologies that
are designed to process and concentrate autologous cells and proteins.
The BMAC system incorporates a proprietary floating-shelf
technology that provides the highest total nuclear cell yield with
established viability and osteogenicity. (1,2)
Until the introduction of Harvest’s BMAC™
System, it was difficult to process and concentrate a clinically
significant dose of adult stem cells from a patient’s
bone marrow at the point of patient care within 15 minutes.
Harvest Technologies is a privately held company based in Plymouth, Mass.
1 Osteogenic differentiation model, performed at the CBR Institute of
Biomedical Research, Boston, 2006. 2 Heeschen, Christopher M.D, et al.
Concentration of Bone Marrow Total Nucleated Cells by a Point of Care
Device Provides a High Yield and Preserves Their Functional Activity.
Cell Transplantation, Vol 16. pp-159-1069, 2008.
Trackback URL: http://www.prweb.com/pingpr.php/U3VtbS1UaGlyLVNpbmctU3VtbS1Ib3JyLVplcm8=
|
